Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Kenobamaatti aikuisilla, joilla on fokaalialkuisia kohtauksia (BLESS)

tiistai 10. marraskuuta 2026 päivittänyt: Aziende Chimiche Riunite Angelini Francesco S.p.A

Kenobamaatti aikuisilla, joilla on fokusalkuisia kohtauksia: tosimaailman monikeskushavainto italialainen

The BLESS Study contributes to filling this information gap by collecting data from the Italian clinical practice and the Compassionate Use Program, to better characterize the clinical profile of cenobamate describing its effectiveness, safety and tolerability in adult patients diagnosed with uncontrolled focal epilepsy despite the use of at least two antiepileptic medicinal products.

Tutkimuksen yleiskatsaus

Yksityiskohtainen kuvaus

The main objective of the study is to describe the effectiveness of adjunctive cenobamate treatment in adult patients with uncontrolled focal epilepsy in Italy, overall and according to age class, setting of cenobamate treatment, cenobamate final target daily dose prescribed, and number of concomitant Anti Seizure Medications (ASMs). This will be assessed by intra-patient percent change and achievement of a ≥50% reduction in the seizure frequency from the pre-treatment baseline over a period of 52 weeks.

Opintotyyppi

Havainnollistava

Ilmoittautuminen (Todellinen)

936

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskelupaikat

    • Bari
      • Bari, Bari, Italia, 70124
        • Policlinico di Bari
    • Catanzaro
      • Catanzaro, Catanzaro, Italia, 88100
        • Università degli Studi di Catanzaro "Magna Graecia"
    • Isernia
      • Pozzilli, Isernia, Italia, 86077
        • IRCCS Neuromed
    • Pavia
      • Pavia, Pavia, Italia, 27100
        • Fondazione Istituto Neurologico Casimiro Mondino
    • Roma
      • Roma, Roma, Italia, 00128
        • Campus Bio-Medico
      • Roma, Roma, Italia, 00161
        • Policlinico Umberto I
    • Torino
      • Torino, Torino, Italia, 10153
        • Humanitas Gradenigo
    • Treviso
      • Conegliano, Treviso, Italia, 31015
        • Associazione La Nostra Famiglia - IRCCS Eugenio Medea
    • Udine
      • Udine, Udine, Italia, 33100
        • Azienda Sanitaria Universitaria (A.O.U.) Integrata
    • Vicenza
      • Vicenza, Vicenza, Italia, 36100
        • Ospedale San Bortolo

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

18 vuotta - 99 vuotta (Aikuinen, Vanhempi Aikuinen)

Hyväksyy terveitä vapaaehtoisia

Ei

Sukupuolet, jotka voivat opiskella

Kaikki

Näytteenottomenetelmä

Todennäköisyysnäyte

Tutkimusväestö

Adult patients diagnosed with focal epilepsy uncontrolled despite the use of at least two antiepileptic medicinal products, treated with adjunctive cenobamate in Italy. A single cohort of patients will be involved in the study, enrolling both subjects who initiated cenobamate treatment in accordance with the current clinical practice, and subjects previously included in the cenobamate Compassionate Use Programme in Italy, provided that they fulfil all of the eligibility criteria listed below

Kuvaus

Inclusion Criteria:

  • Age ≥18 years at the time of cenobamate treatment initiation
  • Male or female patients
  • Patients diagnosed with focal epilepsy uncontrolled despite a history of treatment with at least two antiepileptic medicinal products at the time of cenobamate treatment initiation in agreement with the Summary of Product Characteristics (SmPC)
  • Patients who at enrolment had received at least 12 weeks (titration period up to the initial recommended target dose of 200 mg daily completed) but no more than 52 weeks of cenobamate as adjunctive treatment of focal-onset seizures with or without secondary generalization
  • Patients with available retrospective data in medical charts and seizure diaries, including information about baseline seizure frequency prior to cenobamate treatment initiation
  • Patients who gave written informed consent to take part into the study and personal data processing consent following local regulation.
  • Patients who received adjunctive cenobamate for at least 12 weeks and discontinued permanently treatment before enrolment will also be included in the study-

Exclusion Criteria:

  • Patients diagnosed with familial short-QT syndrome
  • Patients affected by hypersensitivity to the active substance cenobamate or to any of the excipients (e.g., lactose monohydrate)
  • Patients with history of severe drug-induced hypersensitivity reaction, including (but not limited to) drug reaction with eosinophilia and systemic symptoms (DRESS), and Stevens Johnson syndrome
  • Patients enrolled in a clinical trial in which treatments for epilepsy are managed through a study protocol
  • Patient unable to read and write in Italian language and to autonomously fill in questionnaires and scales
  • Patients with a known pregnancy or who are breast-feeding from cenobamate treatment initiation till enrolment visit.

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Havaintomallit: OTHER
  • Aikanäkymät: PROSPECTIVE

Kohortit ja interventiot

Ryhmä/Kohortti
Adult patients diagnosed treated with adjunctive cenobamate in Italy.

Adult patients diagnosed with focal epilepsy uncontrolled despite the use of at least two antiepileptic medicinal products, treated with adjunctive cenobamate in Italy.

A single cohort of patients will be involved in the study, enrolling both subjects who initiated cenobamate treatment in accordance with the current clinical practice, and subjects previously included in the cenobamate Compassionate Use Programme in Italy, provided that they fulfil all of the eligibility criteria listed below

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Absolute frequency of patients achieving a 50 % or greater reduction in the seizure frequency (overall)
Aikaikkuna: 12, 24 and 52 weeks of cenobamate treatment initiation

Seizure frequency during the baseline and post-baseline assessments was calculated by summing the total number of seizures (all types of seizures) reported in each considered period and dividing by the duration of that period (number of days), excluding days with no available diary data, and multiplying by 28 to normalize to a monthly rate ("monthly seizure frequency").

12, 24 and 52 weeks of cenobamate treatment initiation
Relative frequency of patients achieving a ≥50% (50% or greater) reduction in the seizure frequency (overall)
Aikaikkuna: 12, 24 and 52 weeks of cenobamate treatment initiation

Seizure frequency during the baseline and post-baseline assessments was calculated by summing the total number of seizures (all types of seizures) reported in each considered period and dividing by the duration of that period (number of days), excluding days with no available diary data, and multiplying by 28 to normalize to a monthly rate ("monthly seizure frequency").

12, 24 and 52 weeks of cenobamate treatment initiation
Intra-patient percent change in the seizure frequency (overall)
Aikaikkuna: 12, 24 and 52 weeks of cenobamate treatment initiation

Intra-patient percent change from baseline will be defined as [(monthly seizure frequency at post-baseline assessments - monthly seizure frequency at baseline), divided by the monthly seizure frequency at baseline] multiplied by 100.

12, 24 and 52 weeks of cenobamate treatment initiation
Absolute frequency of patients achieving a 50 % or greater reduction in the seizure (stratified)
Aikaikkuna: 12, 24 and 52 weeks of cenobamate treatment initiation

Seizure frequency during the baseline and post-baseline assessments was calculated by summing the total number of seizures (all types of seizures) reported in each considered period and dividing by the duration of that period (number of days), excluding days with no available diary data, and multiplying by 28 to normalize to a monthly rate ("monthly seizure frequency").

Population will be stratified according to the following:

  • Age class of patient at the time of cenobamate treatment initiation (i.e., <65 years; ≥65 years).
  • Setting of cenobamate treatment initiation (i.e., CUP; current clinical practice).
  • Cenobamate final target daily dose prescribed (i.e., 200 mg; >200 mg).
  • Number of ASMs concomitant with cenobamate (i.e., ≤2 ASMs; >2 ASMs).
12, 24 and 52 weeks of cenobamate treatment initiation
Relative frequency of patients achieving a ≥50% (50% or greater) reduction in the seizure frequency (stratified)
Aikaikkuna: 12, 24 and 52 weeks of cenobamate treatment initiation

Seizure frequency during the baseline and post-baseline assessments was calculated by summing the total number of seizures (all types of seizures) reported in each considered period and dividing by the duration of that period (number of days), excluding days with no available diary data, and multiplying by 28 to normalize to a monthly rate ("monthly seizure frequency").

Population will be stratified according to the following:

  • Age class of patient at the time of cenobamate treatment initiation (i.e., <65 years; ≥65 years).
  • Setting of cenobamate treatment initiation (i.e., CUP; current clinical practice).
  • Cenobamate final target daily dose prescribed (i.e., 200 mg; >200 mg).
  • Number of ASMs concomitant with cenobamate (i.e., ≤2 ASMs; >2 ASMs).
12, 24 and 52 weeks of cenobamate treatment initiation
Intra-patient percent change in the seizure frequency (stratified)
Aikaikkuna: 12, 24 and 52 weeks of cenobamate treatment initiation

Intra-patient percent change from baseline will be defined as [(monthly seizure frequency at post-baseline assessments - monthly seizure frequency at baseline), divided by the monthly seizure frequency at baseline] multiplied by 100.

Population will be stratified according to the following:

  • Age class of patient at the time of cenobamate treatment initiation (i.e., <65 years; ≥65 years).
  • Setting of cenobamate treatment initiation (i.e., CUP; current clinical practice).
  • Cenobamate final target daily dose prescribed (i.e., 200 mg; >200 mg).
  • Number of ASMs concomitant with cenobamate (i.e., ≤2 ASMs; >2 ASMs).
12, 24 and 52 weeks of cenobamate treatment initiation

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Absolute frequency of patients achieving a ≥50%/≥75%/≥90%/=100% sustained reduction in the seizure frequency
Aikaikkuna: 24 and 52 weeks of cenobamate treatment initiation.

Sustained seizure frequency reduction will be defined as a ≥50%/≥75%/≥90%/=100% reduction in baseline seizure frequency achieved at 12 weeks of cenobamate treatment initiation, that continues (is sustained) without interruption and without cenobamate permanent discontinuation through the observation period until 24 and 52 weeks of cenobamate treatment initiation, respectively.

24 and 52 weeks of cenobamate treatment initiation.
Absolute frequency of patients achieving a ≥75%/≥90%/=100% reduction in the seizure frequency
Aikaikkuna: 12, 24 and 52 weeks of cenobamate treatment initiation.

Seizure frequency reduction will be defined as a ≥75%/≥90%/=100% reduction in baseline seizure frequency achieved at 12, 24 and 52 weeks of cenobamate treatment initiation, respectively.

12, 24 and 52 weeks of cenobamate treatment initiation.
Relative frequencies of patients achieving a ≥50%/≥75%/≥90%/=100% sustained reduction in the seizure frequency
Aikaikkuna: 24 and 52 weeks of cenobamate treatment initiation.

Sustained seizure frequency reduction will be defined as a ≥50%/≥75%/≥90%/=100% reduction in baseline seizure frequency achieved at 12 weeks of cenobamate treatment initiation, that continues (is sustained) without interruption and without cenobamate permanent discontinuation through the observation period until 24 and 52 weeks of cenobamate treatment initiation, respectively

24 and 52 weeks of cenobamate treatment initiation.
Relative frequencies of patients achieving a ≥75%/≥90%/=100% reduction in the seizure frequency
Aikaikkuna: 12, 24 and 52 weeks of cenobamate treatment initiation.

Seizure frequency reduction will be defined as a ≥75%/≥90%/=100% reduction in baseline seizure frequency achieved at 12, 24 and 52 weeks of cenobamate treatment initiation.

12, 24 and 52 weeks of cenobamate treatment initiation.
Absolute frequency of patients with at least one AE
Aikaikkuna: Through study completion, an average of 1 year

Absolute frequency of patients treated with cenobamate who experienced at least one AE during the applicable observation period

Through study completion, an average of 1 year
Relative frequency of patients with at least one AE
Aikaikkuna: Through study completion, an average of 1 year

Relative frequency of patients treated with cenobamate who experienced at least one AE during the applicable observation period

Through study completion, an average of 1 year
Absolute frequency of patients with at least one ADR
Aikaikkuna: Through study completion, an average of 1 year

Absolute frequency of patients treated with cenobamate who experienced at least one ADR during the applicable observation period

Through study completion, an average of 1 year
Relative frequency of patients with at least one ADR
Aikaikkuna: Through study completion, an average of 1 year

Relative frequency of patients treated with cenobamate who experienced at least one ADR during the applicable observation period

Through study completion, an average of 1 year
Absolute frequency of patients treated with at least one SAE
Aikaikkuna: Through study completion, an average of 1 year

Absolute frequency of patients treated with at least one SAE during the applicable observation period

Through study completion, an average of 1 year
Relative frequency of patients treated with at least one SAE
Aikaikkuna: Through study completion, an average of 1 year

Relative frequency of patients treated with at least one SAE during the applicable observation period

Through study completion, an average of 1 year
Health-Related Quality of life (HRQoL)
Aikaikkuna: 12, 24 and 52 weeks

The Health-Related Quality of life (HRQoL) of patients will be assessed by means of the 31-item Quality Of Life In Epilepsy inventory (QOLIE-31).

The 31-item Quality Of Life In Epilepsy inventory (QOLIE-31) is a patient self-reported instrument that contains 31 items grouped in seven multi-item scales ( "seizure worry", "overall QoL", "emotional well-being", "energy fatigue", "cognitive functioning", "medication effects" and "social functioning"). Different items in the QOLIE-31 have different ranges of precoded numeric values, so the scoring procedure requires conversion from raw, precoded numeric values to scores of 0-100 points, with higher scores reflecting better quality of life. The QOLIE-31 overall score is calculated by summing the product of each scale score times its weight and summing over all scales, according to the instructions obtained from copyright holders.

12, 24 and 52 weeks
Patient Global functioning (CGI-S)
Aikaikkuna: 12, 24 and 52 weeks

The patient global functioning will be assessed by means of the Clinical Global Impression (CGI) Scales. The Early Clinical Drug Evaluation Program (ECDEU) version of the CGI is a 3-item clinician rated scale that measures illness severity (CGI-S), global improvement or change (CGI-I) and treatment response (efficacy index: CGI-E).

The CGI-S score ranges from 1 (normal) through to 7 (amongst the most severely ill patients).

The calculation of the scores will be performed according to the instructions obtained from copyright holders.

12, 24 and 52 weeks
Patient Global functioning (CGI-I)
Aikaikkuna: 12, 24 and 52 weeks

The patient global functioning will be assessed by means of the Clinical Global Impression (CGI) Scales. The Early Clinical Drug Evaluation Program (ECDEU) version of the CGI is a 3-item clinician rated scale that measures illness severity (CGI-S), global improvement or change (CGI-I) and treatment response (efficacy index: CGI-E).

The CGI-I score ranges from 1 (very much improved) through to 7 (very much worse).

The calculation of the scores will be performed according to the instructions obtained from copyright holders.

12, 24 and 52 weeks
Patient Global functioning (CGI-E)
Aikaikkuna: 12, 24 and 52 weeks

The patient global functioning will be assessed by means of the Clinical Global Impression (CGI) Scales. The Early Clinical Drug Evaluation Program (ECDEU) version of the CGI is a 3-item clinician rated scale that measures illness severity (CGI-S), global improvement or change (CGI-I) and treatment response (efficacy index: CGI-E).

The CGI-E score should take account of both therapeutic effect and tolerance, and ranges from 0 (marked improvement and no toxicity) and 4 (unchanged or worse and toxicity outweigh the therapeutic effects). Each component of the CGI is rated separately; the instrument does not yield a global score.

The calculation of the scores will be performed according to the instructions obtained from copyright holders.

12, 24 and 52 weeks
Daytime Sleepiness
Aikaikkuna: 12, 24 and 52 weeks

Daytime Sleepiness will be assessed by means of the Epworth Sleepiness Scale (ESS). The ESS is a self-administered questionnaire with 8 questions. Respondents are asked to rate, on a 4-point scale (0-3), their usual chances of dozing off or falling asleep while engaged in eight different daily activities. The ESS score can range from 0 to 24. The higher the ESS score, the higher that person Average Sleep Propensity in Daily Life (ASP), or their daytime sleepiness across a wide range of activities in their daily lives.

12, 24 and 52 weeks
Hospital Anxiety and Depression
Aikaikkuna: 12, 24 and 52 weeks

Anxiety and depression symptoms will be assessed by means of the the Hospital Anxiety and Depression Scale (HADS). This is a patient self-reported instrument consisting of 14 items that provide scores on two specific subscales: "Anxiety" subscale (HADS-A, 7 items) and "Depression" subscale (HADS-D, 7 items).

All items were scored on a 4-point Likert scale from 0 ("never") to 3 ("almost every day") referring to overt symptoms within the last week. Total scores range from 0 to 21 points for each subscale, with higher scores indicating higher levels of symptoms.

12, 24 and 52 weeks
Retention with cenobamate
Aikaikkuna: 52 weeks

Retention with cenobamate will be assessed by calculating the frequency of patients still on treatment with cenobamate at 52 weeks of treatment initiation.

52 weeks

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Julkaisuja ja hyödyllisiä linkkejä

Tutkimusta koskevien tietojen syöttämisestä vastaava henkilö toimittaa nämä julkaisut vapaaehtoisesti. Nämä voivat koskea mitä tahansa tutkimukseen liittyvää.

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Todellinen)

Tiistai 24. tammikuuta 2023

Ensisijainen valmistuminen (Todellinen)

Tiistai 30. joulukuuta 2025

Opintojen valmistuminen (Todellinen)

Keskiviikko 21. lokakuuta 2026

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Keskiviikko 26. huhtikuuta 2023

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Perjantai 5. toukokuuta 2023

Ensimmäinen Lähetetty (Todellinen)

Tiistai 16. toukokuuta 2023

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Perjantai 13. marraskuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Tiistai 10. marraskuuta 2026

Viimeksi vahvistettu

Sunnuntai 1. marraskuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Ei

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa